Acute kidney injury

EQS-News: How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication

Retrieved on: 
Friday, September 23, 2022

Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.

Key Points: 
  • Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.
  • In fact, each year, more people die from this silent killer than from breast or prostate cancer.
  • Hyperphosphatemia (elevated phosphorus levels in the blood) is a common complication of CKD affecting over 80% of dialysis patients.
  • UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

Global Dialysis Market Report 2022: Growing Number of Diabetic and Hypertension Patients Fueling Sector - ResearchAndMarkets.com

Retrieved on: 
Friday, September 16, 2022

The "Dialysis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dialysis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global dialysis market reached a value of US$ 104.13 Billion in 2021.
  • The growing number of diabetic and hypertension patients along with the increasing incidences of end-stage renal disease (ESRD) are primarily driving the global dialysis market.
  • Additionally, the introduction of sorbent-based regenerative technology that enables the delivery of high-dose dialysis with a low volume of dialysis solution while removing toxins is expected to drive the global dialysis market in the coming years.

Potrero Medical Receives FDA Breakthrough Device Designation for Accuryn AKI Predict Algorithm

Retrieved on: 
Tuesday, September 13, 2022

HAYWARD, Calif., Sept. 13, 2022 /PRNewswire/ -- Potrero Medical announced today that the FDA granted Breakthrough Device Designation for their AKI Predict machine learning algorithm, for the advanced prediction of acute kidney injury (AKI) associated with intra-abdominal hypertension (IAH) in cardiac post-surgical intensive care patients.

Key Points: 
  • HAYWARD, Calif., Sept. 13, 2022 /PRNewswire/ -- Potrero Medical announced today that the FDA granted Breakthrough Device Designation for their AKI Predict machine learning algorithm, for the advanced prediction of acute kidney injury (AKI) associated with intra-abdominal hypertension (IAH) in cardiac post-surgical intensive care patients.
  • Combining Accuryn technology with a predictive AKI algorithm will enhance the clinical decision support we provide at the bedside."
  • To receive breakthrough designation from the FDA, there are several criteria that must be met.
  • First, the device must provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating human disease or conditions.

BioPorto to Participate in H.C. Wainwright’s 24th Annual Global Investment Conference

Retrieved on: 
Thursday, September 8, 2022

COPENHAGEN, Denmark and BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced plans to participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022 in New York City.

Key Points: 
  • COPENHAGEN, Denmark and BOSTON, Sept. 08, 2022 (GLOBE NEWSWIRE) -- BioPorto A/S (BioPorto) (CPH:BIOPOR) today announced plans to participate in the H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022 in New York City.
  • Following are details for managements presentation:
    Management will also be available for 1x1 meetings.
  • Following the conference, the presentation video will be available for three months on BioPortos website at www.bioporto.com .
  • The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange.

Unicycive Reports Key Findings of UNI-494 Efficacy in Preclinical Animal Model of Acute Kidney Injury (AKI)

Retrieved on: 
Wednesday, September 7, 2022

LOS ALTOS, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced key findings of UNI-494 efficacy from a preclinical study in rodent model of Acute Kidney Injury.

Key Points: 
  • LOS ALTOS, Calif., Sept. 07, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced key findings of UNI-494 efficacy from a preclinical study in rodent model of Acute Kidney Injury.
  • The Company evaluated the effect of UNI-494 on ischemia-reperfusion induced acute kidney injury (IR-AKI) in rats.
  • We are excited to report this key finding from the IR-AKI model showing treatment with UNI-494 significantly reduced this key biomarker of kidney injury that is a well-accepted biomarker of proximal renal tubule damage.
  • UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.For more information, please visit www.unicycive.com .

Ketoanalogue for Kidney Disease Market to Rise at a CAGR of 6.5% during Forecast Period, notes TMR Study

Retrieved on: 
Tuesday, September 6, 2022

The rising prevalence of kidney disease and growing use of ketoanalogue supplements in the treatment of renal disease are the two main factors likely to drive the global market for Ketoanalogue for Kidney Disease Market.

Key Points: 
  • The rising prevalence of kidney disease and growing use of ketoanalogue supplements in the treatment of renal disease are the two main factors likely to drive the global market for Ketoanalogue for Kidney Disease Market.
  • Global Ketoanalogue for Kidney Disease Market: Growth Drivers
    Depending on distribution channel, the global market for ketoanalogue for kidney disease is expected to be dominated by hospital pharmacies during the forecast timeframe.
  • The prevalence of kidney illness has increased in North America, which is why the region dominates the global market for ketoanalogue for kidney disease.
  • Global Ketoanalogue for Kidney Disease Market: Key Players
    Global Ketoanalogue for Kidney Disease Market: Segmentation

Unicycive Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference

Retrieved on: 
Tuesday, September 6, 2022

LOS ALTOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Company management will participate at the upcoming H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022 in New York City.

Key Points: 
  • LOS ALTOS, Calif., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc.(Nasdaq: UNCY), a clinical stage biotechnology company developing therapies for patients with kidney disease, today announced that Company management will participate at the upcoming H.C. Wainwright 24th Annual Global Investment Conference taking place September 12-14, 2022 in New York City.
  • Shalabh Gupta, M.D., Chairman and Chief Executive Officer of Unicycive, will virtually present a corporate overview, which will be available On-Demand beginning at 7:00 am ET on Monday, September 12, 2022 through the end of the conference.
  • Unicycive Therapeutics is a biotechnology company developing novel treatments for kidney diseases.
  • Unicycives lead drug, Renazorb, is a novel phosphate binding agent being developed for the treatment of hyperphosphatemia.

Nuwellis Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients

Retrieved on: 
Wednesday, August 31, 2022

A total of 254 CABG procedures were performed during this period, and ultrafiltration was used in 17 (6.7%) patients.

Key Points: 
  • A total of 254 CABG procedures were performed during this period, and ultrafiltration was used in 17 (6.7%) patients.
  • Despite an elevated mean Society of Thoracic Surgeons mortality score of 5.7% (range 0.6-50.0), the 30-day survival rate of patients treated with ultrafiltration was 100%.
  • The Aquadex System offers a significant opportunity to the medical community to improve clinical outcomes.
  • In addition to cardiovascular surgery, Nuwellis continues to make significant progress in other key areas of patient need, including heart failure and pediatrics.

Analysis Group and Pfizer Present Interim Data on COVID-19 Vaccine Safety Surveillance Program Showing No Adverse Safety Signals Among US Veterans Health Administration Patients

Retrieved on: 
Tuesday, August 30, 2022

BOSTON, Aug. 30, 2022 /PRNewswire/ -- During the International Society of Pharmacoepidemiology's annual meeting, researchers from Analysis Group (a global leader in health care consulting), the Veterans Health Administration (VHA), and Pfizer presented interim data from 1,448,043 US veterans who were among the first to receive the Pfizer-BioNTech COVID-19 vaccine, between December 11, 2020, and September 24, 2021. In this interim analysis, no adverse safety signals were found among the study population, who overwhelmingly completed the primary series of two doses (96%). With study completion planned for December 2023, the safety of the vaccine will continue to be evaluated by study investigators.

Key Points: 
  • In this interim analysis, no adverse safety signals were found among the study population, who overwhelmingly completed the primary series of two doses (96%).
  • With study completion planned for December 2023, the safety of the vaccine will continue to be evaluated by study investigators.
  • Analysis Group researchers designed the study protocol and collaborated with the VHA to identify near real-time safety signals among vaccinated individuals over the course of 30 months.
  • Forty-six pre-specified safety events of interest were included in the vaccine safety surveillance program, including cerebrovascular non-hemorrhagic stroke, acute myocardial infarction, chilblain-like lesions, anaphylaxis, and acute kidney injury.

DGAP-News: Interdepartmental testing of the kidney function biomarker penKid in routine care at Heidelberg University Hospital and the Heidelberg Kidney Center

Retrieved on: 
Friday, August 26, 2022

Four units at the University Hospital Heidelberg and Heidelberg Kidney Center implement Proenkephalin (penKid) in a pilot biomarker-based treatment approach to diagnose AKI faster and monitor it more accurately across departments.

Key Points: 
  • Four units at the University Hospital Heidelberg and Heidelberg Kidney Center implement Proenkephalin (penKid) in a pilot biomarker-based treatment approach to diagnose AKI faster and monitor it more accurately across departments.
  • PenKid is a proposed biomarker for real-time kidney function that potentially closes on the gaps of the standard diagnostic procedures.
  • This includes the normal, the intermediate care (IMC), the nephrology, and the intensive care units (ICU) of both clinics in Heidelberg.
  • This routine use of penKid on a centralized level in the hospital drives innovation on multiple wards such as nephrology, ICU and IMC.